Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2723

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 7
Chunk 2723
---
 the Offering. In connection with the services provided by Jones, the Placement Agent
and Jones agreed that the Placement Agent will receive an aggregate fee equal to 6% of the gross proceeds received in the Offering and
Jones will receive an aggregate fee equal to 3% of the gross proceeds received in the Offering. In addition, the Company agreed to reimburse
the Placement Agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $85,000, non-accountable expenses
of up to $25,000 and has agreed to reimburse Jones for all reasonable and documented out-of-pocket fees and expenses, including but not
limited to travel and other out-of-pocket expenses in an amount not to exceed $15,000.

The Company’s directors
and executive officers agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose
of any shares of common stock or other securities convertible into or exercisable or exchangeable for common stock for a period of 90
days following the closing date of the Offering, which terms may be waived in the sole discretion of and without notice by the Placement
Agent, subject to certain exceptions. In addition, the Company has agreed to not enter into variable rate financings for a period of 180
days following the closing date, subject to certain exceptions, or enter into any equity financings for a period of 60 days following
the closing date, subject to certain exceptions.

In connection with the Offering,
the Conversion Price of the Series A Preferred Stock and Series C Preferred Stock reset to $1.96 per share of Common Stock.

On March 4, 2025, the Company’s
Board of Directors granted directors, officers and employees options to purchase up to 406,251 shares of common stock for $1.43 per share.
The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire on March 4, 2035.

On March 10, 2025, the Company
redeemed 316 shares of Series C Preferred Stock from certain investors for a cash payment of $395,000, or $1,250 per share of Series C
Preferred Stock.

F-33

No
No

P5Y
P5Y

0001870404
false
FY

    0001870404

    2024-01-01
    2024-12-31

    000187040